Current and experimental therapeutic options for cytomegalovirus disease.
Flaherty
J F
JF
School of Pharmacy, University of California, San Francisco, CA 94143, USA.
D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000077404:Cidofovir; D003587:Cytomegalovirus; D003586:Cytomegalovirus Infections / Q000188:drug therapy*; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy; D003596:Cytosine / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D017245:Foscarnet / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D015774:Ganciclovir / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006147:Guanine / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D007275:Injections, Intravenous; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
D000998:Antiviral Agents; D003692:Delayed-Action Preparations; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D017245:Foscarnet; D006147:Guanine; D003596:Cytosine; C063638:lobucavir; D000077404:Cidofovir; D015774:Ganciclovir